Previous Blogs

Avatar

By Eecho Wang

June 15, 2021

We are delighted to share that West China has recently received two acknowledgements from China National Pharmaceutical Packaging Association (CNPPA), an industrial authority in China, for West’s continuous efforts in supporting the healthcare industry during the pandemic and insightful sharing on scientific thought leadership.

Avatar

By Candice Sun

December 17, 2020

Technical Guideline for Study of Nitrosamine Impurities in Chemical Drugs (Trial) was issued by the China National Medical Products Administration on 8 May 2020. This guideline discusses nitrosamine impurities in drug products, including the sources of nitrosamine impurities and the control strategy. The control strategy is given from the perspectives of the basic concept of control, control limits, establishment of analytical methods, and control of risk throughout the drug product lifecycle.

Avatar

By Lynn Yao

April 13, 2020

The Standing Committee of the National People’s Congress in China passed the revised Drug Administration Law (Revised Law) on 26-Aug-19. Effective 1-Dec-19, it is the first overhaul since 2001. The Revised Law addresses the major issues in the pharmaceutical industry, demonstrating the government’s efforts in strengthening supervision to ensure drug safety.

Avatar

By Lynn Yao

April 03, 2020

With the continuous progress in medical science and technology, drug evaluation criteria in China are also changing and improving. In the past, drug evaluation criteria did not require generic drugs to have the consistent quality and efficacy of innovator drugs; so some had a gap in efficacy. Since 2015, the National Medical Products Administration of China (NMPA), formerly the China Food and Drug Administration (CFDA), rolled out the Generic Quality and Efficacy Consistency Evaluation (GQEC) to improve the quality and efficacy of generic drugs. Generic drugs whose quality and efficacy are deemed equivalent to innovator drugs will enjoy preferential treatment in public hospitals and prescriptions.

Avatar

By Qian Lui

February 28, 2018

It has been over a year since China Food and Drug Administration (CFDA) announced Matters Concerning Bundling Review and Approval of Pharmaceutical Packaging Materials, Pharmaceutical Excipients and Drugs (Document No.134 [2016]). As a result, the China pharmaceutical packaging industry is experiencing a revolution.

Avatar

By Lynn Yao

January 26, 2018


In 2016, the China Federal Drug Administration (CFDA) made two announcements regarding packaging of parenteral drug products. Per these announcements, stability studies of packaging materials should refer to protection, compatibility, safety and functionality properties.